Poly(ADP-ribose) polymerase inhibitor olaparib has recently received FDA approval for treatment of ovarian cancer with mutated BRCA1/2 and EMEA approval for maintenance therapy for platinum-sensitive ovarian cancer (77). Here, BRCA1 is linked to ovarian carcinoma.